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Abstract  Microbiome is the community of commensal, symbiotic and pathogenic microorganism that share our 
human body space. Intestinal microbiota has a defensive role in human health, it is implicated in metabolic and 
nutritional processes and plays an important role in the pathophysiology of several diseases. In recent years special 
attention has been paid to investigations targeting the changes of intestinal microbiome in various gastrointestinal 
disorders including inflammatory bowel disease, infectious colitis and celiac disease (CD). The aim of our present 
review is to summarize the role of the microbiome in CD and the changes of its composition in the intestine of 
patients suffering from CD. 
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1. Introduction 
Celiac disease (CD) also known as gluten-sensitive 
enteropathy or nontropical sprue is a chronic immune-
mediated enteropathy of the small intestine induced by 
dietary gluten and related prolamins [1,2]. Most of the 
prolamin proteins - present in wheat, rye and barley - may 
contain immunogenic epitopes causing adverse symptoms 
of CD through the induction of inflammatory responses of 
the intestinal mucosa which lead to villous atrophy and 
malabsorption [3,4,5,6]. 
CD develops more frequently in genetically 
predisposed individuals, it has been associated with the 
major histocompatibility complex region. More than 90% 
of CD patients express the antigen-presenting molecules 
human leukocyte antigen (HLA)-DQ-2/2.2/8, however 
only in a part of HLA-DQ-2/2.2/8 positive individuals 
develops CD (40% of the population carries these 
haplotypes without any evidence of CD) [6]. Based on 
recent epidemiological studies, similarly to other immune-
mediated diseases (allergy or asthma) CD may appear at 
any age and its prevalence is continuously increasing [1]. 
These observations assume that beside genetic 
predisposition there are other factors which contribute to 
the pathogenesis of CD such as environmental factors, diet 
and microbiome [5]. The aim of the recent review is to 
introduce the possible role of the microbiome in the gut 
and in the pathomechanism of CD. 
2. Microbiome in the Gut  
The human body is inhabited by a large amount of 
bacteria, viruses and archaea. Most of them are localized 
in the gastrointestinal tract (colon contains 70% of all 
microbes). Gut colonization starts during birth with the 
passage through the birth canal and is followed by a 
gradual microbiome change until young adulthood. 
Caesarian delivery can also affect the early biodiversity of 
the intestine [7]. The composition of the microbiome 
depends on genetic background, geographic determinants, 
and diet as well [8,9]. 
Gut is the primary site of the interaction between the 
microorganisms and host immune system [10] and the 
balanced intestinal microbiome is responsible for the 
physiological development of the (gut) immune system. 
The intestinal microbiome promotes immune maturation 
and tolerance through the activation of immune responses 
leading to the expression of immunoglobulins and 
cytokines including interleukin-8, -10, -17, -21, -22, and 
interferon-γ [5,11]. 
The luminal surface of the gut is covered by a mucous 
layer, which contains binding sites for commensal microbes 
and prevents the direct contact of the enterocytes with 
pathogens [8]. Moreover, bacteria and their components 
and metabolic products – defensins, cathedicilins, short-
chain fatty acids - provide the host to stimulate the 
production of antimicrobial substances [8]. Examination 
of faecal samples from healthy individuals revealed 
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limited overlap in the microbial composition between the 
individuals, but certain phylotypes occur more commonly 
than others. The most common bacteria in the healthy 
duodenum are the Bacilli, Streptococcaceae, Actinobacteria, 
Actinomycinaeae and Corynebacteriaceae in bacterial 
concentration of 103 cells/g [8].  
Identification of the dominant intestinal bacterial 
species and the effect of diet, age, body weight and drugs 
(antibiotics, steroids) on the colonization are crucial to 
uncover the impact of the gut microbiota on human health 
[12,13]. Clinical and experimental studies confirmed that 
the gut microbiota plays an important role also in the 
pathogenesis of several disorders including obesity, 
diabetes, atopic diseases and it contributes to the 
development of CD as well [11,14]. 
The bacterial peptide glycans and polysaccharides are 
recognized by antigen presenting cells through their 
specific pattern recognition receptors including toll-like 
receptors (TLRs) and their co-receptor the cluster of 
differentiation 14 (CD14). Activation of these receptors 
contributes to the increased expression of inflammatory 
cytokines, initiating infiltration of lymphocytes into the 
lamina propria, villous atrophy, crypt hyperplasia, which 
are all characteristic for CD [15]. Also toxic gliadin 
fragments may induce TLR signaling and regulates the 
expression of tight junction proteins. The activation of 
those pathways can lead to the damage of the epithelial 
barrier and increased intestinal permeability, which 
facilitate the access of higher antigen (bacterial antigens 
and prolamins) loads [5].  
3. Detection of the Intestinal Microbiome 
Examination of the intestinal microbiota is complicated 
due to the dominance of anaerob bacteria and the 
difficulties of their culturing [16]. In the past few years the 
revolution of gene sequencing and bacterial phylogenetic 
microarrays made it possible to comprehensively study the 
human intestinal microbiome through the identification of 
bacteria-specific regions with oligonucleotide probes [17]. 
After DNA extracting and next-generation sequencing of 
the bacterial 16S ribosomal (r)RNA more accurate and 
realistic results compared to regular bacterial cultures can 
be obtained [16]. 16S rRNA, a component of prokaryotic 
ribosomes is used as the most common genetic marker, 
which contains nine “hyper-variable” regions and species-
specific sequences within a variable region. These species-
specific sequences serve astargets for scientific research 
and diagnostic assay developmentallowing us the 
comprehensive and high revolution analysis of microbiota 
composition [5,18]. 
4. Microbiome in CD 
Recent studies demonstrated that the composition of the 
intestinal microbiota in patients with CD differs from that 
of healthy individuals [5]. The gastrointestinal tract is 
covered by a mucous glycocalyx layer, which carbohydrate 
structures represents attachment sites for host bacteria [3]. 
Inherited differences in the expression of carbohydrates 
may lead to the colonization of certain strains of bacteria, 
which influences the susceptibility of the individuals to 
CD. Also the presence of certain bacterium species may 
cause environmental changes predisposing CD independently 
from genetic background through the alteration of 
carbohydrate expression [3]. Indeed the ratio of beneficial 
to harmful bacterial strains was significantly lower in 
patients with CD compared to healthy controls and was 
intermediate in patients following gluten free diet (GFD) 
[19].  
De Palma et al. measured the effect of GFD over a 
month in healthy subjects, they found out that GFD led to 
the reduction of beneficial gut bacteria populations, which 
is in contrary to the results in CD patients. They also 
found out that GFD stimulates the host immunity [20]. 
Differences in the microbiota of patients with CD 
compared to healthy controls have been studied mostly in 
faeces, however there is an increased number of studies in 
the local, mucosa associated bacterial composition from 
biopsies. Recent studies investigating the major bacterial 
phylotypes in the duodenal mucosa of CD patients 
compared to healthy individuals demonstrated that 
Proteobacteria, Bacilli and Bacteroidetes were dominant 
in both groups and there was no significant difference 
between the bacterial diversity of each groups in major 
phylotypes [5]. Investigating the sub-population profile 
they found eight genus-like bacterial groups in duodenal 
biopsies which distinguish CD patients from healthy 
controls. Bacteria in the duodenum of patients with CD 
are Prevotella, Haemphilus, Serratia, that of healthy 
controls are Prevotellaoralis et rel., Proteus et rel., 
Clostridium stercorarium et rel., Ruminococcusbromii et 
rel., Papillibactercinnamivorans et rel. [5]. 
Patients with active CD had a higher amount of total 
bacteria, increased level of harmful Gram-negative 
bacteria (Bacteroides, Prevotella, Escherichia (E.) coli) 
and a lower number of Gram-positive bacteria including 
the protective Lactobacilli and Bifidobacteria [8,19,21,22]. 
This dysbiosis was only partially normalized after GFD 
[23]. 
Similarly, Nadal et al. and Collado et al. studying the 
intestinal microbiome found also that Bacterioidetes and E. 
coliwere significantly more abundant in the duodenal 
biopsies from pediatric patients with CD, which returned 
to normal in patients who had been on GFD for 1-2 years 
[19]. Also Collado et al. found that the local and faecal 
microbiota composition were similar [21]. Increased level 
of Bacteroides and Clostridium without any increment in 
the amount of E. coli was also detected in biopsies and 
faeces in GFD-treated patients compared to the CD group. 
E. coli maybe associated with the active phase of the 
disease generating mucosal lesions and atrophy [21]. 
Recent studies confirmed that the level of rod-shaped 
bacteria (Bacillus, Firmicutes) was elevated in the 
duodenal mucosa of pediatric patients with active CD and 
in GFD-treated children as well [24]. 
Sanchez et al. confirmed that there is a lower level of 
the protective phylum Firmicutes and Streptococceae and 
an elevated level of Proteobacteria, Enterobacteriacae, 
Staphylococceae and Klebsiella in patients with CD [25]. 
The same research group examined the differences in 
Bacteroides spp. and their pathogenic features confirm an 
increased abundance of Bacterioides fragilis strains with 
metalloprotease activity [22,25]. They demonstrated that 
patients with active CD showed the highest Renyi 
diversity values followed by the non-active CD patients 
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and healthy individuals, which was used to determine 
differences in bacterium species among study groups. 
Renyi diversity index was lower in the duodenal biopsies 
of patients maintained on GFD and control individuals 
[25]. 
In conclusion, there are significant differences between 
the duodenal bacterial composition of patients with newly 
diagnosed CD and that of treated patients maintained on 
GFD. Lifelong lasting GFD, which is recently the only 
effective treatment of CD, only partially contribute to the 
restoration of the intestinal microbiome, the imbalance is 
maintained even after treatment [22]. 
The prevalence of small intestine bacterial overgrowth 
(SIBO) in CD is not well known, because of the 
limitations in diagnosis, but it is considered as a potential 
cause for non-responsive CD [26]. Galatola et al. have 
shown a high prevalence of SIBO in CD (25%), and 
another studies demonstrated even higher prevalence in 15 
non-responsive CD (66%) [27,28]. Following antibiotic 
(rifaximin) treatment the patients with non-responsive CD 
were symptom free [28]. 
The microbiota of infants, which were genetically 
predisposed (HLA-DQ-2 and/or 8) to CD, differs from 
that of non-predisposed children. Recent studies reported a 
reduced amount of Bacteroides, Escherichi/Shigella and 
Clostridiumin genetically predisposed infants [29]. In 
contrary another study showed increased level of 
Bacteroides fragilis and Staphylococci and decreased 
amount of Bifidobacteria in genetically susceptible infants. 
Palma et al. also found a difference between the 
microbiome compositions of breast-fed (Bifidobacterium 
species) or formula-fed (Enterobacteriaceae, Streptococcus, 
Bacteroides, Clostridium, and Bifidobacterium) infants 
with and without carrying HLA-DQ-2 haplotypes. 
Moreover breast-feeding reduced the genotype-related 
differences in microbiota composition which may partly 
explain the protective role of breast milk in many 
disorders [30]. These studies suggest that the genotype 
and diet determine the gut colonisers. Main changes in the 
microbiome composition found in patients with CD 
compared to controls are shown in Table 1. 
Table 1. Microbiome changes in CD. The table shows major groups 
of microbes that were increased or decreased in patients with active 
CD compared to control individuals 
Increased in CD  Decreased in CD  
Bacteroides [8,19,21] Lactobacilli [8,19,21] 
Proteobacteria [25] Bifidobacteria [8,19,21] 
Prevotella [5] Streptococcaceae [25] 
Haemphilus [5] Firmicutes [25] 
Serratia [5]  
E. Coli [19]  
Enterobacteriacae [25]  
Stapyholoccaceae [25]  
Klebsiella [25]  
Bacilli [5]  
Bacterioidetes [5]  
Clostridium [21]  
 
Further studies are required to explore the complex 
functions of the microbiome, there cognition of the 
bacterial dysbiosis in patients with CD led to the 
exploration of possible benefits of probiotic formulas to 
improve the symptoms of CD. 
5. Conclusions 
Overall it seems to be unequivocal, that CD is 
associated with the overgrowth of pathobionts resulting in 
decreased number of protective symbiont and commensal 
colonies in the small intestine. Alteration of the intestinal 
microbiota may be consequence of the massive destruction of 
the duodenal mucosa, the release of proinflammatory 
markers and other cell-derived factors, which may foster 
the colonization of harmful Gram-negative bacteria in 
genetically predisposed individuals inducing the loss of 
tolerance against prolamins.  
The severity of the disease also determines the 
composition of the microbiome parallel to the activation 
or remission of the mucosal lesions suggesting that the 
presence of some bacterium species may be a biological 
marker of disease activity.  
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